GlassScriptPhysician profile
Andrew Scott Robinson
NPI 1881103588
$4,443.47
in general payments reported to CMS, 2019-2025
30 companies · $866 in 2025
The $866 reported for 2025 was more than what 85% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $678 · 2022: $432 · 2023: $1,714 · 2024: $753 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,333.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,158.09 | 2021-2025 | |
| Amgen INC. | $692.93 | 2021-2025 | Uplizna, Repatha |
| Abbvie INC. | $481.98 | 2021-2024 | |
| Axsome Therapeutics, INC. | $240.82 | 2024-2025 | Auvelity |
| Alexion Pharmaceuticals, INC. | $208.49 | 2023-2024 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $175.74 | 2023-2025 | Rexulti |
| Neurelis, INC. | $167.27 | 2021-2024 | Valtoco |
| Neurocrine Biosciences, INC. | $158.21 | 2022-2024 | Ingrezza, Ongentys |
| Inspire Medical Systems, INC. | $122.55 | 2023 | Inspire |
| Jazz Pharmaceuticals INC. | $114.07 | 2021-2023 | |
| Novo Nordisk INC | $109.00 | 2023 | |
| Ucb, INC. | $101.80 | 2023-2024 | Briviact, Fintepla |
| Emd Serono, INC. | $101.35 | 2024 | |
| Sk Life Science, INC. | $100.71 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $80.21 | 2021-2024 | Austedo Xr |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $78.48 | 2023 | Azstarys |
| Grifols USA, LLC | $57.61 | 2021-2023 | Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $39.24 | 2023-2024 | Hyqvia |
| Kyowa Kirin, INC. | $37.86 | 2023 | Nourianz |
| Eisai INC. | $37.37 | 2021-2023 | |
| Acadia Pharmaceuticals INC | $24.30 | 2023 | Daybue |
| Pfizer INC. | $21.16 | 2023 | |
| Janssen Pharmaceuticals, INC | $18.85 | 2021 | |
| Genzyme Corporation | $18.63 | 2023 | |
| Catalyst Pharmaceuticals, INC. | $18.49 | 2023 | Fycompa |
| Tanabe Pharma America, INC. | $16.94 | 2024 | |
| Tg Therapeutics, INC. | $16.85 | 2023 | |
| Chiesi USA, INC. | $15.67 | 2023 | Kengreal, Cleviprex |
| Scilex Pharmaceuticals INC. | $14.80 | 2023 | Ztlido |
| Lilly USA, LLC | $14.00 | 2023 | Emgality |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.